LEVIN 400 MG

A useful way to understand Imatinib is to start with the biology it targets. Inhibits BCR-ABL, KIT and PDGFRA tyrosine kinases. The target is a disease-defining tyrosine-kinase pathway in Philadelphia chromosome-positive leukemia, making molecular disease status central to its use. The database classifies it as Targeted Therapy; BCR-ABL Tyrosine Kinase Inhibitor and associates it with CML; ALL; GIST. Its principal oncology indications are CML; Philadelphia chromosome-positive ALL; KIT-positive GIST; selected PDGFRA/KIT-driven tumors. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are Imatinib monotherapy; adjuvant GIST therapy; Ph-positive leukemia regimens. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. Beyond BCR-ABL inhibition in CML and Ph-positive ALL, the record specifically includes KIT-positive GIST and selected PDGFRA/KIT-driven tumors. The pharmacology helps explain its individual position among related medicines. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.